Loading…
← CockpitCompetitor Analysis › BMY Bristol Myers SquibbOpen in the cockpit ↗

Bristol Myers SquibbBMYCompetitor analysis, valuation and peers

United States · USD·Health Care›Pharmaceuticals: Major

Branded pharma with major oncology (Opdivo), hematology (Eliquis, Revlimid) and neuroscience (Cobenfy) franchises.

Momentum neutral 49
Mkt cap
$122B
US dollars, full cap
Free float
100%
of shares outstanding
$/day
$640M
20-day average traded
Fwd P/E
9.2×
forward earnings
ROIC−WACC
+17.1 pp
WACC 6.3%
Hurdle
-16 pp
Req g minus delivered
Official | Implied
A / A+
agencies · bond market
Next earnings
78 days
4 Feb 2027
Close · USD$59.56
1D-2.9%
1W-5.3%
1M-3.4%
3M-9.0%
6M+2.9%
YTD+14.2%
1Y+31.5%
ATR %3.1%
Beta0.26
52w lowhigh13.2% off high

What Bristol Myers Squibb does

Branded pharma with major oncology (Opdivo), hematology (Eliquis, Revlimid) and neuroscience (Cobenfy) franchises.

Sells patented medicines through health systems and payers, with much of revenue from a handful of drugs, several of which lose patent protection this decade. Eliquis is shared with Pfizer. The 2019 Celgene purchase brought Revlimid, and Cobenfy came from the 2024 Karuna deal.

Products and services

  • Opdivo (oncology)
  • Eliquis (anticoagulant)
  • Cobenfy (schizophrenia)
  • Revlimid (hematology, generics eroding)

Customers

  • Oncologists/cardiologists
  • Health systems
  • Payers

Where it sits in the supply chain

  • Pharmaceuticals
  • Branded biopharma
  • Oncology, hematology, neuroscience

What could go right

  • Cobenfy launch in schizophrenia/other indications
  • New oncology combination approvals

What could go wrong

  • Revlimid/Eliquis patent cliffs
  • Long-term Opdivo biosimilar competition risk

Moat: narrow (IP / patents, scale). Strong patent-protected franchises but facing near-term loss of exclusivity on key products.

Headquarters: New York, New York, United States · Founded: 1989 · Employees: 32,500

Named competitors

Bristol Myers Squibb at a glance

Size Bristol Myers Squibb (BMY) is a United States Health Care company (Pharmaceuticals: Major) with a market value of $122B, the 102nd largest of 3,085 United States companies the cockpit tracks. Shares closed at $59.56 on 18 Nov 2026.

Performance Over six months the shares gained 2.9%, against +12.0% for the median peer and -2.2% for the United States market (cap-weighted) — 7th lowest of 21 in its peer set.

Growth Revenue grew 4.2% over the last twelve months (peer median +6.1%); the operating margin is 32.9% (peer median 24.0%).

Valuation It trades at 9.2× forward earnings against a peer median of 17.5× (cheapest of 21).

Price implies For today's price to make sense, revenue must grow about -13% a year for seven years (Req g). Recent delivered growth is +3%, so the hurdle is -16 pp: the price already allows for a slowdown.

Capital Return on invested capital runs 17.1 points above its cost of capital (6.3% WACC).

Credit Bristol Myers Squibb has 34 bonds outstanding ($36.0B), rated A by the agencies and trading like A+ at a weighted spread of 76 bp.

Short interest Short interest is 2.3% of the free float (30 Oct 2026).

Next results Next results expected around 4 Feb 2027 (exchange calendar; dates can move).

Relative performance

9010011021 May 202621 Aug 202618 Nov 2026Peer median 113BMY 101
Six months, rebased to 100: Bristol Myers Squibb against the median of its 20 peers (local-currency closes).

Bristol Myers Squibb financials

Reported figures in USD; fiscal year ends 2025-12-31. TTM = trailing twelve months.
TTMFY2025FY2024FY2023FY2022
Revenue$50.0B$48.2B$48.3B$45.0B$46.2B
Revenue growth—0%+7%-2%—
Gross profit$33.2B$31.8B$27.4B$25.4B$26.5B
EBITDA$19.4B$19.2B$19.3B$18.3B$19.6B
Net income$9.24B$7.05B-$8.95B$8.03B$6.33B
Free cash flow$9.29B$12.8B$13.9B$12.7B$11.9B
Capital expenditure$1.37B$1.31B$1.25B$1.21B$1.12B
Total debt$44.8B$47.1B$51.2B$41.5B$40.7B

Quarterly statements and history in the cockpit →

Bristol Myers Squibb competitor charts

The default views of Competitor Analysis ▸ Charts, drawn from the same data. Open them in the cockpit to change the axes, pin companies and read every value.

Performance: 6-month against 1-month return

0%+20%+40%0%+10%SANVRTXGSKREGNPFENOVO-B4519MRK4502603259BAYNAZNNOVNGALDSUNPHARMA600276688235MRKSDZ4578BMY6-month return →1-month return →
Up and to the right = strong over both horizons. Bristol Myers Squibb is the large dot.

Fundamentals: revenue growth against valuation

0%+10%+20%20×40×SANVRTXGSKREGNPFENOVO-B4519MRK4502603259BAYNAZNNOVNGALDSUNPHARMA600276688235MRKSDZ4578BMYRevenue growth (TTM) →Forward P/E →
Further right = faster growth; higher = more expensive. The dashed lines are the peer medians. Bristol Myers Squibb is the large dot.

Capital: growth delivered against growth the price implies

0%+25%+50%+75%0%50%SANVRTXGSKREGNPFENOVO-BMRK603259AZNGALDSUNPHARMA600276688235BMYGrowth delivered (Del g) →Growth the price implies (Req g, 7 yrs) →
Above the diagonal = the price needs more growth than the company has been delivering; below = the price already allows for a slowdown. Bristol Myers Squibb is the large dot.

Bristol Myers Squibb competitors and peer comparison

Head to head with its named competitors (BMY vs MRK vs ABBV vs JNJ)
CompanyMarket cap6M returnRevenue growthOp. marginForward P/EReq g
Bristol Myers Squibb BMY$122B+3%+4%33%9.2×-13.1%
Merck & MRK$340B+23%+5%18%16.4×8.3%
AbbVie ABBV$506B+35%+11%36%18.1×-0.1%
Johnson & Johnson JNJ$656B+20%+8%26%24.2×3.7%
Pfizer PFE$160B+9%+1%26%9.9×-4.3%

How Bristol Myers Squibb compares with its peers

Peer set: Industry: the same industry and sector in any market, nearest in size. This is the same default set the interactive Competitor Analysis opens with.

Bristol Myers Squibb against its 20 peers (data as of 18 Nov 2026)
MeasureBMYPeer medianRank in peer set
1-month return-3.4%+4.3%3rd lowest of 21
6-month return+2.9%+12.0%7th lowest of 21
Distance from 52-week high-13.2%-7.4%8th lowest of 21
Revenue growth (TTM)+4.2%+6.1%6th lowest of 21
Operating margin32.9%24.0%5th highest of 21
Forward P/E9.2×17.5×cheapest of 21
Growth the price implies (Req g, 7 yrs)-13.1%6.2%least demanding of 20
Growth delivered (Del g)+2.5%+9.3%4th lowest of 20
Hurdle (Req g minus delivered)-15.7 pp-3.4 pp3rd least demanding of 20
ROIC minus cost of capital+17.1 pp+4.8 pp6th highest of 21
EV / EBITDA7.9×14.9×3rd cheapest of 19
Net debt / EBITDA1.7×1.2×8th most indebted of 19
Bond spread76 bp70 bp6th widest of 14

Peer table

Peer set: Industry: the same industry and sector in any market, nearest in size
CompanyMarketMarket cap6M returnRevenue growthOp. marginForward P/EReq gDelivered g
Bristol Myers Squibb BMYUnited States$122B+3%+4%33%9.2×-13.1%+2.5%
Sanofi SAN.PAFrance$114B+13%+15%27%9.7×-4.8%+3.9%
Vertex Pharmaceuticals VRTXUnited States$136B+25%+11%35%28.5×6.2%+14.2%
GSK GSK.LUnited Kingdom$97.9B-3%+4%25%10.4×-0.1%-0.9%
Regeneron Pharmaceuticals REGNUnited States$97.8B+46%+19%30%11.8×-1.1%+11.0%
Pfizer PFEUnited States$160B+9%+1%26%9.9×-4.3%+8.5%
Novo Nordisk A/S NOVO-B.CODenmark$177B-6%+6%48%11.8×-0.5%+19.5%
Chugai Pharmaceutical 4519.TJapan$75.2B-8%+17%50%23.7×5.0%+9.8%
Merck KGaA MRK.DEGermany$71.3B+16%+1%19%17.4×7.4%+3.8%
Takeda Pharmaceutical 4502.TJapan$69.8B+30%+6%18%51.0×3.7%+7.1%
WuXi AppTec 603259.SSChina$64.2B+40%+32%43%17.0×7.2%+22.3%
Bayer BAYN.DEGermany$60.3B+48%0%13%12.3×n/an/a
AstraZeneca AZN.LUnited Kingdom$278B-2%+5%23%17.6×14.4%+15.7%
Novartis NOVN.SWSwitzerland$285B+11%-4%30%17.5×1.6%-0.2%
Galderma GALD.SWSwitzerland$51.9B+18%+16%19%45.7×18.0%+6.4%
Sun Pharmaceutical Industries SUNPHARMA.NSIndia$48.0B-1%+12%23%36.0×28.7%+11.7%
Jiangsu Hengrui Pharmaceuticals 600276.SSChina$45.7B-13%+6%27%33.4×13.4%+2.7%
BeOne Medicines 688235.SSChina$45.5B+9%+25%18%59.7×19.1%+79.3%
Merck & MRKUnited States$340B+23%+5%18%16.4×8.3%+9.3%
Sandoz SDZ.SWSwitzerland$41.7B+26%+1%15%24.5×7.5%+0.4%
Otsuka Hldgs 4578.TJapan$39.9B+9%+11%18%16.8×1.6%+11.7%

Bristol Myers Squibb bonds and credit

Bristol Myers Squibb has 34 bonds outstanding with $36.0B face value. The agencies rate it A; its bonds trade like A+. Weighted yield 5.72%, a spread of 76 bp over government bonds.

Every bond, yield and spread in the cockpit →

Questions

Who are Bristol Myers Squibb's main competitors?
Named competitors: Merck (MRK), AbbVie (ABBV), Johnson & Johnson (JNJ), Pfizer (PFE). The cockpit's measured peer set (industry) also includes Sanofi (SAN.PA), Vertex Pharmaceuticals (VRTX), GSK (GSK.L), Regeneron Pharmaceuticals (REGN), Pfizer (PFE), Novo Nordisk A/S (NOVO-B.CO).
Is Bristol Myers Squibb expensive compared with its peers?
On forward p/e it trades at 9.2× against a peer median of 17.5×, cheapest of 21 in its peer set. For today's price to make sense, revenue must grow about -13% a year for seven years (Req g). Recent delivered growth is +3%, so the hurdle is -16 pp: the price already allows for a slowdown.
How has Bristol Myers Squibb stock performed?
Over six months to 18 Nov 2026 the shares returned +2.9% against +12.0% for the median peer; over one year +31.5%.

How these numbers are made. Returns are close-to-close in local currency. Revenue growth and margins are trailing twelve months. Req g is the revenue growth that today's enterprise value requires for seven years at the company's own cost of capital; Delivered g is what it actually grew; the gap is the hurdle (honest precision about ±8 points, so read the ranking more than the decimal). No fair values, price targets or analyst ratings are shown, by design. Method and validation.